About Vigene Biosciences
Vigene Biosciences is a Healthcare company based in Rockville (United States) founded in 2012, and was acquired by Charles River Laboratories in May 2021. Research reagents for drug discovery and functional genomics are developed. Vigene Biosciences has raised $10.5 million across 2 funding rounds from investors including Charles River Laboratories and Signet Healthcare Partners. The company has 45 employees. Vigene Biosciences has completed 1 acquisition, including Omnia Biologics. Its chief executive, as recorded, is Zairen Sun. Vigene Biosciences offers products and services including Plasmid DNA Manufacturing, Viral Vector Manufacturing, Cell Therapy Manufacturing, Viral Vector Packaging, and Custom Cloning. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its legal entity is VIGENE BIOSCIENCES, INC. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Vigene Biosciences was founded in 2012 in Rockville, United States, and operates within the life sciences sector. Reagents for drug discovery and functional genomics are developed, with a portfolio that includes adeno-associated virus products, lentiviruses, human cDNA clones, mammalian expression vectors, and molecular bioreagents. Services provided encompass plasmid and adenoviral cloning, lentiviral cloning, AAV packaging, TALE nuclease design, and shRNA cloning, supporting research in biotechnology applications.
- Headquarters Rockville, United States
- Employees 45
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website vigenebio.com
- Social LinkedIn X
- Acquired by Charles River Laboratories (May 2021)
- Legal Name Vigene Biosciences, Inc.
- Total Equity Funding$10.5M (USD)
in 2 rounds
- Latest Funding Round$3M (USD), Series A
Mar 2020
- InvestorsCharles River Laboratories
& 1 more
- Employee Count45
- Investments & Acquisitions
- Acquired byCharles River Laboratories
(May 2021)
Products & Services of Vigene Biosciences
Vigene Biosciences offers a comprehensive portfolio of products and services, including Plasmid DNA Manufacturing, Viral Vector Manufacturing, Cell Therapy Manufacturing, Viral Vector Packaging, and Custom Cloning.
Produces plasmid DNA for gene therapy applications to support research and development.
Develops viral vectors for delivering gene therapies in clinical and commercial settings.
Manufactures cell-based therapies for treating various diseases through advanced processes.
Packages viral vectors to ensure stability and efficacy for therapy applications.
Provides customized cloning services for biotechnology and therapeutic research needs.
Funding Insights of Vigene Biosciences
Vigene Biosciences has successfully raised a total of $10.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.5M
- Total Rounds 2
- Last Round Series A — $3M
- First Round $7.5M
(May 2019)
- Investors Count 1
All 2 funding rounds of Vigene Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2020 | $3M | Series A | – | – | – |
| May 2019 | $7.5M | Series A | – | Signet Healthcare Partners | – |
2 investors in total: 2 institutional.
Investors in Vigene Biosciences
Vigene Biosciences has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Charles River Laboratories and Signet Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in North America and Europe | signethealthcarepartners.com | New York, United States | ||
Provider of drug discovery and preclinical development services | 1947 | criver.com | Wilmington, United States |
Investor details for Vigene Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vigene Biosciences
6 people are tracked at Vigene Biosciences (6 in leadership); the tracked headcount is 45.
| Name | Role | Group |
|---|---|---|
Zairen Sun | CEO | Leadership |
Dr. Audrey Chang | Vice President of QC & Analytical Services | Leadership |
Jeffrey Hung | General Manager | Leadership |
Chien-Chien Jacques | Vice President of Finance & Accounting | Leadership |
James Boykin | Senior Director of Quality Assurance | Leadership |
Patrick DePalma | Vice President of Business Development | Leadership |
Complete people profiles for Vigene Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vigene Biosciences
Vigene Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Omnia Biologics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Process development and manufacturing services for biologics are provided. | omniabio.com | Rockville, United States | 2001 | Nov 2016 | •••• |
Complete acquisition details for Vigene Biosciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Vigene Biosciences
5 dated milestones of Vigene Biosciences across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Vigene Biosciences is founded.
- Acquisition Acquires Omnia Biologics.
- Funding First funding round of $7.5M.
- Funding Latest funding round, Series A, of $3.0M.
- Exit Acquired by Charles River Laboratories.
Competitors of Vigene Biosciences
Vigene Biosciences has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Vigene Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vigene Biosciences
Websites that share an audience with Vigene Biosciences (vigenebio.com).
Websites whose visitors overlap most with Vigene Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sourcebioscience.com | 100% | 10.5K | #1,618,265 | View details | |
| transomic.com | 77% | View details | |||
scholar.google.ca | scholar.google.ca | 50% | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Vigene Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vigene Biosciences
Complete news archive for Vigene Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vigene Biosciences
Vigene Biosciences was founded in 2012 and raised its 1st funding round 7 years after it was founded.
Vigene Biosciences is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Zairen Sun is the CEO of Vigene Biosciences, as recorded in our data.
Vigene Biosciences is a funded company, having raised a total of $10.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $7.5M, raised on May 2019.
Vigene Biosciences has 45 employees.
Vigene Biosciences was founded in 2012 in Rockville, United States, and operates within the life sciences sector. Reagents for drug discovery and functional genomics are developed, with a portfolio that includes adeno-associated virus products, lentiviruses, human cDNA clones, mammalian expression vectors, and molecular bioreagents. Services provided encompass plasmid and adenoviral cloning, lentiviral cloning, AAV packaging, TALE nuclease design, and shRNA cloning, supporting research in biotechnology applications.
Vigene Biosciences's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Vigene Biosciences offers Plasmid DNA Manufacturing, Viral Vector Manufacturing, Cell Therapy Manufacturing, Viral Vector Packaging, and Custom Cloning.
Vigene Biosciences has made 1 acquisition, including Omnia Biologics.
Vigene Biosciences has 2 investors. Key investors include Charles River Laboratories, and Signet Healthcare Partners.
Vigene Biosciences operates through Vigene Biosciences, Inc..
Yes. Vigene Biosciences was acquired by Charles River Laboratories in May 2021.